Primmune Therapeutics

Primmune Therapeutics is a clinical-stage biopharmaceutical company based in Carlsbad, California.

The company focuses on developing orally administered, small-molecule TLR7 agonists aimed at enhancing the innate immune system for cancer and viral disease immunotherapy. Its lead product, PRTX007, is a novel oral systemic TLR7 agonist designed to promote immune signaling toward interferon-associated responses while reducing pro-inflammatory pathways. PRTX007 is being developed as a TherAjuvantTM candidate for treating acute viral diseases, pre-cancerous lesions, and advanced cancers, including solid tumors and HPV-related cervical conditions. Primmune aims to activate specific immune pathways to improve the effectiveness and durability of existing immunotherapy treatments for patients.